ArticleCancers2020
Aptamer-Conjugated Superparamagnetic Ferroarabinogalactan Nanoparticles for Targeted Magnetodynamic Therapy of Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.Journal of nanobiotechnology · 2026Review
- Preparation and Evaluation of Docetaxel-Loaded Targeted Poly (β‑amino Ester) - Magnetic Nanoparticles for Chemo‑Magnetodynamic Therapy Under Low‑Frequency Magnetic Fields.International journal of nanomedicine · 2026Article
- Article
- Arabinogalactan-Functionalized Gold Nanoparticles Demonstrated Remarkable Anticancer Therapeutic Effect against Hepatocellular Carcinoma.Molecular pharmaceutics · 2025Article
- Engineering Stimuli-Responsive Materials for Precision Medicine.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Rational Design of Pectin-Chitosan Polyelectrolyte Nanoparticles for Enhanced Temozolomide Delivery in Brain Tumor Therapy.Biomedicines · 2024Article
- Vincristine-based nanoformulations: a preclinical and clinical studies overview.Drug delivery and translational research · 2024Review
- Development of DNA aptamers for visualization of glial brain tumors and detection of circulating tumor cells.Molecular therapy. Nucleic acids · 2023Article
- Magnetic Nanoscalpel for the Effective Treatment of Ascites Tumors.Journal of functional biomaterials · 2023Article
- Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma.Journal of clinical medicine · 2022Review
- Core-Shell FeMaterials (Basel, Switzerland) · 2022Article
- Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy.Pharmaceutics · 2022Review
- Multifunctional Iron Oxide Magnetic Nanoparticles for Biomedical Applications: A Review.Materials (Basel, Switzerland) · 2022Review
- Aptamers used for molecular imaging and theranostics - recent developments.Theranostics · 2022Review
- Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.International journal of molecular sciences · 2020Review
- Characterizing Interhelical Interactions of G-Protein Coupled Receptors with the Fragment Molecular Orbital Method.Journal of chemical theory and computation · 2020Article
- Aptamers Increase Biocompatibility and Reduce the Toxicity of Magnetic Nanoparticles Used in Biomedicine.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnologies involving physical methods of tumor destruction using functional oligonucleotides are promising for targeted cancer therapy. Our study presents magnetodynamic therapy for selective elimination of tumor cells in vivo using DNA aptamer-functionalized magnetic nanoparticles exposed to a low frequency alternating magnetic field. We developed an enhanced targeting approach of cancer cells with aptamers and arabinogalactan. Aptamers to fibronectin (AS-14) and heat shock cognate 71 kDa protein (AS-42) facilitated the delivery of the nanoparticles to Ehrlich carcinoma cells, and arabinogalactan (AG) promoted internalization through asialoglycoprotein receptors. Specific delivery of the aptamer-modified FeAG nanoparticles to the tumor site was confirmed by magnetic resonance imaging (MRI). After the following treatment with a low frequency alternating magnetic field, AS-FeAG caused cancer cell death in vitro and tumor reduction in vivo. Histological analyses showed mechanical disruption of tumor tissues, total necrosis, cell lysis, and disruption of the extracellular matrix. The enhanced targeted magnetic theranostics with the aptamer conjugated superparamagnetic ferroarabinogalactans opens up a new venue for making biocompatible contrasting agents for MRI imaging and performing non-invasive anti-cancer therapies with a deep penetrated magnetic field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.